Valvular & structural heart diseaseCohort study
Transcatheter Tricuspid Valve Replacement With the Novel System
- Prospective single-arm study
- multicentre
Authors' conclusion
The 1-year outcomes of the TRAVEL study showed a sustained reduction in TR among patients who underwent LuX-Valve TTVR, accompanied by significant right heart reverse remodeling and improved functional status.
Study context
- Population
- Patients with symptomatic severe tricuspid regurgitation (TR) at high surgical risk
- Participants
- 126 patients
- Outcome
- All-cause mortality and hospitalization for HF
- Follow-up
- 1-year follow-up
Main finding
As reported in the abstract
All-cause mortality and HF hospitalization · 1 year
All-cause mortality
10.3%
Hospitalized for HF
4.0%
Observational data: associations, not effects.
Further findings
TR reduced to mild or less · 1 year
- TR mild or less
- 95.2% (P < 0.001)
Right atrial systolic volume · 1 year
- Change in right atrial systolic volume
- −38.3 ± 21.7 mL (P < 0.001)
Mid RV end-systolic diameter · 1 year
- Change in mid RV end-systolic diameter
- −6.4 ± 2.3 mm (P < 0.001)
NYHA class I or II · 1 year
- NYHA class I or II achieved
- 79.8% (P < 0.001)
6-minute walk distance · 1 year
- Increase in 6-minute walk distance
- 71.3 ± 42.8 m (P < 0.001)
Original publication
Transcatheter Tricuspid Valve Replacement With the Novel System. JACC Cardiovasc Interv. Published 9 April 2025. doi:10.1016/j.jcin.2024.12.030
Summarised from the published abstract; every number is checked against it